Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment

RECOMMENDED

Lung Cancer

Variation between multidisciplinary tumor boards in clinical staging and treatment recommendations for patients with locally advanced non-small cell lung cancer

★ 2 Recommended by Dr Martin Frey, Faculty Member

Chest.

Hoeijmakers F, Heineman DJ, Daniels JM, Beck N, Tollenaar RAEM, Wouters MWJM, Marang-van de Mheen PJ, Schreurs WH, MDT study group

doi: 10.1016/j.chest.2020.07.054.

RECOMMENDED

Lung Cancer

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial

★ 1 Recommended by Dr Andreas Müller, Faculty Member

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Oncol

Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Swiss Group for Clinical Cancer Research (SAKK).

doi: 10.1200/JCO.21.00276

RECOMMENDED

Lung Cancer

Definitive treatment patterns and survival in stage II non-small cell lung cancer

doi: 10.1016/j.lungcan.

RECOMMENDED

Lung Cancer

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

★ 1 Recommended by Prof. Dr Stephan Bodis, Faculty Member

★ 2 Recommended by Alexander Meisel, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Oncol.

Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ

doi: 10.1016/S1470-2045(19)30519-4.

Lung Cancer

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

Lancet Respir Med.

Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang DD, Thress KS, Yang JC

COMMENTED

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

Lancet Respir Med.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M

doi: 10.1016/S2213-

Lung Cancer

The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States

Clin Lung Cancer.

Cushman TR, Jones B, Akhavan D, Rusthoven CG, Verma V, Salgia R, Sedrak M, Massarelli E, Welsh JW, Amini A

doi: 10.1016/j.cllc.2020.09.004.

RECOMMENDED

Lung Cancer

Local ablative treatment for synchronous single organ oligometastatic lung cancer - A propensity score analysis of 180 patients

Lung Cancer.

Frost N, Tessmer A, Schmittel A, van Laak V, Raspe M, Ruwwe-Glösenkamp C, Brunn M, Senger C, Böhmer D, Ochsenreither S, Temmesfeld-Wollbrück B, Furth C, Schmidt B, Neudecker J, Rückert JC, Suttorp N, Witzenrath M, Grohé C

doi: 10.1016/j.lungcan.

RECOMMENDED

Lung Cancer

Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug

Lung Cancer.

Stahel RA, Curioni-Fontecedro A, Rohrmann S, Dafni U, Sandner U, Opitz I, Andratschke N, Franzen D, Dimopoulou G, Matthes KL, Kohler M, Guckenberger M, Weder W

doi: 10.1016/j.lungcan.2020.05.037.

Related content

Variation between multidisciplinary tumor boards in clinical staging and treatment recommendations for patients with locally advanced non-small cell lung cancer

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial

Definitive treatment patterns and survival in stage II non-small cell lung cancer

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States

Local ablative treatment for synchronous single organ oligometastatic lung cancer - A propensity score analysis of 180 patients

Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug